Phase III Results Position Selecta/Sobi’s SEL-212 As Tough Competition For Krystexxa In Gout

 
• By Alaric DeArment
  
Selecta and Sobi posted positive topline results from their Phase III trials of SEL-212 in chronic refractory gout • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D